A002630 Stock Overview
Operates in the bio-industry in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ORIENT BIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩477.00 |
| 52 Week High | ₩632.00 |
| 52 Week Low | ₩408.00 |
| Beta | 0 |
| 11 Month Change | 6.71% |
| 3 Month Change | -1.45% |
| 1 Year Change | -21.67% |
| 33 Year Change | -60.08% |
| 5 Year Change | -21.89% |
| Change since IPO | -91.07% |
Recent News & Updates
Shareholder Returns
| A002630 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 8.4% | 0.5% | 0.9% |
| 1Y | -21.7% | 33.0% | -3.4% |
Return vs Industry: A002630 underperformed the KR Life Sciences industry which returned 33% over the past year.
Return vs Market: A002630 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A002630 volatility | |
|---|---|
| A002630 Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A002630 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A002630's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | n/a | Jae-Jin Chang | www.orient.co.kr |
ORIENT BIO Inc. operates in the bio-industry in South Korea. It produces laboratory animals; and offers various equipment for research environment. The company was formerly known as Orient Co., Ltd.
ORIENT BIO Inc. Fundamentals Summary
| A002630 fundamental statistics | |
|---|---|
| Market cap | ₩56.91b |
| Earnings (TTM) | -₩6.85b |
| Revenue (TTM) | ₩59.09b |
0.0x
P/S Ratio0.0x
P/E RatioIs A002630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A002630 income statement (TTM) | |
|---|---|
| Revenue | ₩59.09b |
| Cost of Revenue | ₩37.84b |
| Gross Profit | ₩21.25b |
| Other Expenses | ₩28.10b |
| Earnings | -₩6.85b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A002630 perform over the long term?
See historical performance and comparison